TPP Market Access
Target product profiles – a lost art?

What do your target product profiles (TPP) say about you? Are you the pragmatist? The dreamer? Or maybe the pessimist? Fortunately, we cannot gauge your personality type from the TPP, or at least we should not be able to. We should, however, be able to understand enough about your product to gauge the potential value […]

Market Access
Navigating the future of oncology market access

According to many payers, the high prices of oncology medicines are not sustainable and there remains a gap between drug price and value.1 The rising costs of drug development, increased clinical demand and the need to recoup the cost of failed products, have led to new cancer treatments that come with a high price tag. […]

value added medicines
Challenges for the adoption of value added medicines

Pharmaceutical and life science companies are confronted with increasing competition while working with limited resources, driving the need to improve their internal capability to innovate. Developing new innovative products, however, requires investments, commitment, time, and product potential. How can companies simultaneously work within budget and deliver innovation and value? This dilemma is fuelling the need […]

pharma asset commercialisation
Taking a multipronged approach to commercialisation of assets

Pharmaceutical companies invest in pipeline assets that are scientifically attractive. In reality, only a fraction of assets in development make it to market. The success rate of asset developmental candidates from 2006 to 2015 was reportedly only 9.6%.1 At every phase of asset development, there is a risk of failing to proceed to the next […]

Pharmaceutical pricing
Value-Based Pricing – the way forward?

In an effort to contain costs and avoid the over-valuing of products, payer organisations in the pharmaceutical and life science industries have made price setting a standard practice. One solution that potentially prevents over-valuation of medicines is External Reference Pricing (ERP). However, with greater amounts of data due to research and technological developments, increased adoption […]

PRO data
Curbing non-adherence with PRO data

On average, it is estimated that over 50% of patients eventually abandon their treatment. Patient-reported outcomes (PROs) could facilitate efforts to reduce these figures. Defined as any data coming directly from patients about how they feel or function in relation to a health condition or its treatment – with no clinician interpretation to remove the […]

Biosimilars Access
How can biosimilars support patient access?

Uncertainties about interchangeability still surround biosimilars. Despite regulatory changes that aid the approval process and the promise of affordability, the use of these drugs has been met with mixed reactions – some experts see the value of having alternatives while others question the quality and immunogenicity of biosimilars. In addition, discussions around cost are raising […]

Payer Centricity
Maximising the value story through payer-centricity

Patient-centricity is a key focus for drug and device development. While they may not be the customers, the patients are the final end-users of the drug development, promotion and distribution processes. And if the patients don’t adhere to their treatment, or don’t persist in taking the drug or using the device, this can have a […]

Real-world patient data
Generating insights with real-world patient data

Generation of real-world data is on the increase, from smartphones and social media to medical records and clinical trials. This wealth of data has a huge amount of potential, but in order to make the most of it, life science companies need to focus on generating the right kind of insights from the megabytes of […]

Marker Access
Market access: are payers adversaries or partners to better patient outcomes?

For many years, the route to market access has been focused around completing clinical trials and meeting the safety and efficacy data needs of the regulators. This data is then used to persuade payers that the therapeutic is safe and works, and is therefore worth paying the price demanded. However, as budget cuts bite, competition […]